A pragmatic and successful approach to the treatment of non-small cell carcinoma
of the lung.
For example, for both TTF-1- and napsin A- IHC lung non-small cell carcinomas
, the RNAscope assays for TTF-1 and napsin A can be considered to increase the diagnostic sensitivity and reduce the number of cases with an equivocal diagnosis.
Regional, extrapleural, and distant metastatic disease so adversely affect the prognosis of patients with non-small cell carcinoma
of the lung (NSCCL) that surgical resection is not an appropriate option for treatment in most patients with stage III and IV disease (ie, patients with regional mediastinal or distant spread of disease, respectively), at least not until they have received preoperative therapy.
In summary, cytotechnologists had significantly higher concordance rates for non-small cell carcinoma
and adenocarcinoma, while pathologists performed better for carcinoid tumor (Table 3).
Of note, the frequency of EGFR mutations in non-small cell carcinoma
of the lung has been reported to be 33.
A study of DeltaNp63 expression in lung non-small cell carcinomas
Four cases had to be left classified as non-small cell carcinoma
because the slides were not available for review.
Description of these tumors, based upon the histomorphologic features present at the time of diagnosis, included metastatic carcinoma, possible metastasis, or consistent with metastatic UCa (n 5 23 of 30), poorly differentiated carcinoma (n 5 6 of 30), or moderately differentiated non-small cell carcinoma
(n = 1 of 30).
8) Because the treatment options depended on whether or not the lung cancer was small cell carcinoma versus any of the non-small cell carcinoma
cell types, a diagnosis by the pathologist of non-small cell carcinoma
, rather than a specific cell-type of the latter, was acceptable clinically in many situations.
6-mm tissue cores from adenocarcinomas, squamous cell carcinomas, non-small cell carcinoma
not otherwise specified, and large cell carcinomas collected between 1978 and 2002.
The contribution of the surgical pathologist to patient care was largely restricted to differentiating small cell carcinoma from non-small cell carcinoma
on small biopsies and cytology specimens and to staging of nonsmall cell carcinoma resections.
The traditional role of the pathologist has been primarily to differentiate small cell carcinoma from non-small cell carcinoma
on biopsy and cytology specimens and to stage non-small cell carcinomas
that underwent resection.